TCIM
LCTX icon

TIAA CREF Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

TIAA CREF Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$723K Buy
552,246
+198,931
+56% +$247K ﹤0.01% 2456
2018
Q4 		$323K Sell
353,315
-53,822
-13% -$82.5K ﹤0.01% 2745
2018
Q3 		$837K Sell
407,137
-106,950
-21% -$225K ﹤0.01% 2509
2018
Q2 		$927K Buy
514,087
+3,946
+0.8% +$7.94K ﹤0.01% 2523
2018
Q1 		$1.2M Buy
510,141
+278,211
+120% +$652K ﹤0.01% 2340
2017
Q4 		$436K Buy
231,930
+21,755
+10% +$47.5K ﹤0.01% 2831
2017
Q3 		$522K Sell
210,175
-27,494
-12% -$68.2K ﹤0.01% 2808
2017
Q2 		$655K Buy
237,669
+34,836
+17% +$97.3K ﹤0.01% 2738
2017
Q1 		$612K Buy
202,833
+7,601
+4% +$21.6K ﹤0.01% 2726
2016
Q4 		$617K Sell
195,232
-22,707
-10% -$69.7K ﹤0.01% 2765
2016
Q3 		$744K Sell
217,939
-17,985
-8% -$49.7K ﹤0.01% 2684
2016
Q2 		$539K Buy
235,924
+29,887
+15% +$73.3K ﹤0.01% 2826
2016
Q1 		$517K Sell
206,037
-17,382
-8% -$38.8K ﹤0.01% 2773
2015
Q4 		$739K Hold
223,419
– – ﹤0.01% 2751
2015
Q3 		$541K Hold
223,419
– – ﹤0.01% 2864
2015
Q2 		$655K Buy
223,419
+13,963
+7% +$54.1K ﹤0.01% 2884
2015
Q1 		$840K Hold
209,456
– – ﹤0.01% 2714
2014
Q4 		$631K Sell
209,456
-9,805
-4% -$26.5K ﹤0.01% 2885
2014
Q3 		$556K Sell
219,261
-14,954
-6% -$36K ﹤0.01% 2930
2014
Q2 		$577K Buy
234,215
+27,763
+13% +$62.7K ﹤0.01% 2979
2014
Q1 		$548K Hold
206,452
– – ﹤0.01% 2913
2013
Q4 		$600K Buy
206,452
+18,610
+10% +$56.2K ﹤0.01% 2910
2013
Q3 		$576K Buy
187,842
+6,457
+4% +$20.4K ﹤0.01% 2894
2013
Q2 		$580K Buy
+181,385
New +$581K ﹤0.01% 2885

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

TIAA CREF Investment Management's LCTX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Lineage Cell Therapeutics (LCTX) stake by 56% in Q1 2019, buying an estimated $247K and bringing the position to 552,246 shares worth $723K. The position accounts for ﹤0.01% of the portfolio, ranked #2456.

TIAA CREF Investment Management first reported a position in LCTX in Q2 2013 and has held it in 24 quarters since. The position peaked at $1.2M in Q1 2018. 118 funds tracked by Wall St. Rank hold LCTX as of Q1 2019.

  • TIAA CREF Investment Management held 552,246 shares of Lineage Cell Therapeutics worth $723K as of Q1 2019.
  • TIAA CREF Investment Management bought 198,931 Lineage Cell Therapeutics shares in Q1 2019, an estimated $247K.
  • Lineage Cell Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2456 holding.
  • TIAA CREF Investment Management first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Lineage Cell Therapeutics position peaked at $1.2M in Q1 2018.
  • 118 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.